Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

745P - Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial

Date

14 Sep 2024

Session

Poster session 01

Topics

Targeted Therapy

Tumour Site

Ovarian Cancer

Presenters

Qinglei Gao

Citation

Annals of Oncology (2024) 35 (suppl_2): S544-S595. 10.1016/annonc/annonc1592

Authors

Q. Gao1, H. Zhang2, H. Zheng3, R. An4, J. Jiang5, Q. Li6, Z. Chen7, J. Li8, G. Li9, R. Li10, R. Xie11, D. Ma1

Author affiliations

  • 1 Department Of Gynecology And Oncology, Tongji Hospital Affiliated Tongji Medical College, Huazhong University of Science and Technology, 430030 - Wuhan/CN
  • 2 Department Of Gynecology And Oncology, Hubei Cancer Hospital, 430079 - Wuhan/CN
  • 3 Department Of Gynecology And Oncology, Peking University Cancer Hospital and Institute, 100142 - Beijing/CN
  • 4 Department Of Gynecology And Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061 - Xi'an,/CN
  • 5 Department Of Gynecology And Oncology, Qilu Hospital of Shandong University, 250012 - Jinan/CN
  • 6 Department Of Gynecology And Oncology, Shandong Cancer Hospital Affiliated to Shandong University, 250117 - Jinan/CN
  • 7 Department Of Gynecology And Oncology, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), 230031 - Hefei/CN
  • 8 Gyneacological Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 9 Department Of Gynecology And Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 - Wuhan/CN
  • 10 Chongqing University Cancer Hospital, Chongqing University Cancer Hospital, 400030 - Chongqing/CN
  • 11 Department Of Gynecology And Oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 745P

Background

Platinum-resistant, recurrent ovarian cancer (PROC) has poor prognosis with limited treatment options. The BRIGHT trial (NCT05044871) aimed to evaluate the efficacy and safety of biomarker-driven targeted combinatorial therapies of pamiparib (Pami, a PARP inhibitor), tislelizumab (TIS, a PD-1 inhibitor), bevacizumab (BEV), and nab-paclitaxel (nab-PTX) in pts with PROC. Here, we report the primary analysis results.

Methods

Pts with PROC were assigned based on their BRCA mutation status and CD8+ TILs count to receive Pami + BEV (Arm 1, BRCAm; N=40), TIS + BEV + nab-PTX (Arm 2, BRCAwt and CD8+ TILs ≥3; part 1 [N=50], part 2 [N=20]), or BEV + nab-PTX (Arm 3, BRCAwt and CD8+ TILs <3; N=50). The Bayesian method was used to update ORR observed in part 1 of Arm 2. Primary endpoints were ORRs of each arm, and ORR in part 1 of Arm 2.

Results

105 pts were enrolled and assigned to Arm 1 (N=29), Arm 2 (N=70), and Arm 3 (N=6). Most pts with BRCAwt tumors (92.1%; 70/76) had positive CD8+ TILs (≥3). ORRs in each arm were 23.1%, 41.5%, and 60.0%, respectively (Table); ORR in part 1 of Arm 2 was 46.0% (95% CI 31.8-60.7). Pts with higher CD8+ TILs tended to have higher ORR in Arm 2 (CD8+ TILs ≥12, 50.0% [24/48]; CD8+ TILs ≥3 - 1 mo - ≤3 mo 9 (31.0) 20 (28.6) 2 (33.3) >3mo - ≤6 mo 11 (37.9) 32 (45.7) 2 (33.3) Efficacy # N=26 N=65 N=5 ORR, % (95% CI) 23.1 (9.0, 43.7) 41.5 (29.4, 54.4) 60.0 (14.7, 94.7) DCR, % (95% CI) 73.1 (52.2, 88.4) 76.9 (64.8, 86.5) 100.0 (47.8, 100.0) Median PFS, mo (95% CI) 4.1 (1.4, NA) 7.3 (4.8, 8.2) 11.7 (3.4, NA) Median DoR, mo (95% CI) NA (2.8, NA) 5.9 (4.3, 9.1) 8.8 (7.3, NA)

∗Based on safety analysis set.

#based on efficacy analysis set.

§from last platinum to subsequent disease progression.

Conclusions

These findings highlight the potential clinical benefits of biomarker-driven targeted therapies in pts with PROC. The majority of pts in this study had BRCAwt tumors with positive CD8+ TILs (≥3), and PD-1 inhibitor-based combinatorial regimen (TIS + BEV + nab-PTX) resulted in notable ORR and PFS in this patient population.

Clinical trial identification

NCT05044871.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

BeiGene Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.